# C3i Attended the 2026 Summit4CI \- CentreC3i

**URL:** [View](https://c3i.creativedotdesign.com/c3i-attended-the-2026-summit4ci/)

**Last Updated:** 2026-04-27T19:10:52+00:00

**Other languages:** [Français](https://c3i.creativedotdesign.com/fr/c3i-etait-present-au-summit-4ci-2026/)

From March 29 to 31, 2026, **C3i** participated in the **Summit for Cancer Immunotherapy (Summit4CI)**, organized by **BioCanRx** in Vancouver. This annual event brings together scientists, clinicians, industry leaders, and patient advocates committed to advancing immuno-oncology.

At the event, **Jamie Sharp,** **Director of Business Development at C3i**, represented the organization to engage with the teams behind several of the most promising immunotherapy programs.

Discussions focused in particular on a key challenge for the sector: the importance of integrating manufacturing strategy from the very start of a program’s development. Whether it involves **CAR-T** therapies, **NK** cells, viral vectors, or other advanced approaches, the needs related to process development, regulatory compliance, scaling up, clinical manufacturing, and commercialization must be anticipated from the earliest stages.

In this fast-changing environment, **C3i** continues to position itself as an expert and reliable partner, providing the necessary support from development through commercial production, in accordance with **GMP**.

Participating in **Summit4CI 2026** enabled C3i to strengthen its presence in the immunotherapy ecosystem and continue strategic discussions with key players shaping the future of cell and gene therapies.